Modelling the impact of microbiome on immunotherapy efficacy in metastatic melanoma patients
Background: The gut microbiota has garnered interest as a predictor of the effects of immunotherapies in cancer patients. Previous studies have identified specific fecal taxa and metabolites linked to positive treatment outcomes in patients with unresectable cutaneous melanoma undergoing targeted or immunotherapy. Our study aims to investigate the gut microbiome's potential as a predictor of immunotherapy response in metastatic melanoma patients.
Authors
- Míriam Potrony (ORCID: https://orcid.org/0000-0003-2766-0765)
- Teresa Torres (ORCID: https://orcid.org/0000-0003-3847-2647)
- Cristina Carrera (ORCID: https://orcid.org/0000-0003-1608-8820)
- J. Mateu (ORCID: https://orcid.org/0000-0002-0586-1200)
- Judit Companys (ORCID: https://orcid.org/0000-0003-1485-0818)
- Pedro Iglesias (ORCID: https://orcid.org/0000-0003-0126-1985)
- Josep Malvehy (ORCID: https://orcid.org/0000-0002-6998-914X)
- N. Calbet
- Susana Puig (ORCID: https://orcid.org/0000-0003-1337-9745)
Institutions
- Instituto de Salud Carlos III (ES)
- Hospital Clínic de Barcelona (ES)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Universitat de Barcelona (ES)
Publication Details
- Journal
- EJC Skin Cancer
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.ejcskn.2025.100490
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00